• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Clinical benefit seen with ibrutinib for relapsed/refractory multiple mantle cell lymphoma in a real-world population

byKathleen Lau
March 11, 2021
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen 

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines

Tags: bloodblood cancerBruton’s tyrosine kinase (BTK) inhibitorcancerhematologylymphomamantle cell lymphomamcloncologyrelapsed mantle cell lymphomarelapsed or refractory mantle cell lymphomatki
Previous Post

#VisualAbstract: Circulating tumor DNA levels may predict treatment response in patients with advanced melanoma

 Next Post

Screening plus Eave Tubes provides a cost-effective strategy to alleviate burden of malaria in Côte d’Ivoire

RelatedReports

Shorter overall survival among patients with monoclonal gammopathy of undetermined significance
Chronic Disease

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

December 24, 2025
2 Minute Medicine Rewind March 4, 2019
Chronic Disease

Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen 

December 10, 2025
Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
Cardiology

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines

December 8, 2025
Severity of emphysema on pulmonary CT may predict lung cancer location
Chronic Disease

Age-Based Screening for Lung Cancer Surveillance in the US

November 26, 2025
Next Post
RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

Screening plus Eave Tubes provides a cost-effective strategy to alleviate burden of malaria in Côte d’Ivoire

Epidemiologic features of the 2018-2019 measles outbreak in New York City

Study details societal costs of a measles outbreak

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Resuming oral anticoagulant (OAC) therapy after an OAC-related bleed associated with higher rates of bleeding

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial
  • Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry
  • Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.